Introduction
The 2 1-amino acid peptide endothelin-(ET-I )' has surprisingly potent and wide ranging biologic activities. Originally isolated as a potent vasoconstrictor from the supernatant of cultured porcine aortic endothelial cells ( 1 ) it has been further identified in several other tissues (2) (3) (4) (5) . ET-I stimulates mitogenesis in 3T3 fibroblasts, vascular smooth muscle cells and mesangial cells (6) (7) (8) (9) . It causes the release of atrial natriuretic factor from atrial and ventricular cells, activates the transcription of cardiac-specific genes ( 10, 11) , inhibits the release of renin from glomeruli (12) , and induces the release of tissue-Received for publication 1 June 1992 and in revised form 29 September 1992.
1. Abbreviations used in this paper: ang II, angiotensin II; ET-1, endothelin-1; preproET-1, preproendothelin-1; 3'-UTR, 3 ' untranslated region.
type plasminogen activator and prostanoids ( 13, 14) . These findings have led to the suggestion that ET-I may play an important role in cellular signaling mechanisms which extend beyond its well documented vasopressor effects.
Human ET-1 is derived from a 212 amino acid peptide precursor (preproET-1) encoded by a single gene located on chromosome 6 (15, 16) . The human ET-I gene consists of five exons distributed over 6.8 kb of genomic DNA ( 17) . Pre- proET-1 includes a functional 17 amino acid signal peptide which allows the protein to enter the secretory pathway ( 18) . BigET-1, which differs from ET-I in having an extension of 17 amino acids at the carboxy terminus, is the largest precursor of ET-I so far identified in vivo ( 19, 20) . The existence of an endothelin-converting enzyme cleaving bigET-1 into mature 2 1-amino acid peptide ET-I has been postulated ( 1 ) . Recently we demonstrated that human preproET-1 is fully processed by microinjected Xenopus oocytes (21 ) and recombinant baculovirus-infected insect cells (22) , suggesting that common pathways of preproET-1 maturation exist among different cells. Moreover, ultrastructural analysis demonstrates that endothelial cells do not possess substantial numbers of secretory granules (23) . Thus, ET-I is probably constitutively released from cells after intracellular processing. ET-I production and secretion may therefore be regulated at the level of mRNA transcription. Indeed, preproET-1 mRNA levels can be modulated by a variety of factors. Transforming growth factor-: (TGF-j3), thrombin, and a thromboxane A2 analogue stimulate endothelin 1 mRNA synthesis in human mesangial cells in culture (5) . PreproET-1 mRNA is constitutively expressed in cultured endothelial cells and levels of transcripts are increased by angiotensin II (ang II), TGF-,B, and thrombin ( 1, 19) . Furthermore, PDGF-A, TGF-0, ang II, arginine-vasopressin, and ET-I itself, stimulate preproET-1 mRNA transcription in rat vascular smooth muscle cells in culture (24) . PreproET-1 mRNA is extremely unstable with a half-life of -15 min ( 17) . The instability ofpreproET-1 mRNA probably results from the presence of two conserved AUUUA sequences in the 3'-untranslated region (3'-UTR) that mediate selective mRNA degradation.
Recently, two DNA sequences in the preproET-1 gene located at position -148 to -117 (region A) and -117 to -98 (region B) were found to be important for constitutive expression of preproET-1 gene in endothelial cells in culture (25). Moreover a GATA-like protein responsible for controlling preproET-1 gene expression at least in endothelial cells and which binds to region A in the preproET-1 promoter has been identified and cloned (26, 27) .
In this paper, we describe the isolation of a novel 5'-extended preproET-1 mRNA that contains functional promoter sequences. This raises the possibility that the preproET-1 gene may be regulated by different promoters. To investigate this question we characterized the 5'-flanking region of the human preproET-1 gene demonstrating that it can be transcribed from two alternative promoter element. Interestingly, analysis ofthe tissue distribution ofthe two mRNAs shows a tissue-type specificity for mRNA-2 in brain and heart tissues. We also identify a short nucleotide sequence in the downstream promoter responsible for ET-1 cell-type specific expression. Our results suggest the existence of different mechanisms controlling ET-1 gene expression in renal epithelial cells as compared to endothelial cells.
Methods
RNA preparation. Total cellular RNA was isolated by lysis in 4 M guanidium isothiocyanate and ultracentrifugation over a CsCl cushion as previously described (28) . Human brain and heart poly(A)+ RNA were from Clontech (Palo Alto, CA).
Sequencing of genomic DNA and cDNA clones. Sequences were obtained on both strands using Sequenase (United States Biochemicals Corp., Cleveland, OH) and standard dideoxy sequencing methodology (29 Polymerase chain reaction. 20 ,g oftotal placenta was reverse transcribed, as described for primer extension, with a specific oligonucleotide (oligo 3: 5'-AGGCGCAGGACCCGTTCGCC-3'), located within the 5'-UTR of mRNA-l and mRNA-2. After extraction with phenol/ chloroform and ethanol precipitation, the pellet was dissolved in 40 M1 H20. The PCR reactions on the first stranded cDNA, were performed according to the published procedures (30) . Amplification cycles were: 1 min at 60°C, 2 min at 72°C, and 45 s at 94°C.
Construction ofpromoter deletion mutants. Deletion mutants ofthe 5'-flanking sequence of the human preproET-1 gene were obtained by PCR. This technique was used to amplify selectively DNA fragments from a plasmid containing most of the 5'-flanking region of the preproET-l gene. In each case was used a set of primers having HindIll linkers at their 5' ends. Each fragment was amplified with a common reverse primer (5'-AGATCTCAAAGCGATCCTTCA-3') and the following sense primers: (5'-GAGCTCTGATGTTATTTTTAAGCTC- 3 ', for -647CAT); (5'-GCTGCACGTTGCCTGTTGGTG-3', for -127CAT); (5'-ACACAATAACATTGTCTGGGGCTG-3', for -99CAT); (5'-AAGTCGGAGCTGTTTACCCCCACT-3', for -70CAT) and (5'-AAGCCGGCAGAGAGCTGTCCAAT-3', for -25CAT). A different reverse primer was used (5'-CCGGAGATA-AGCCAGGCCCCGA-3') in the case of( -127; -647) construct. Amplifications were performed from 1 ng of plasmid DNA by 30 cycles consisting of 30 s at 94°C, 1 min at 65°C, and 1 min at 72°C, as described (30) . The amplified fragments were HindIII digested, purified from the gel, and inserted into the HindIII site upstream of the CAT gene ofthe pCAT-basic plasmid (Promega Corp., Madison, WI).
The correct orientation and sequence of each deletion mutant was further confirmed.
Transfection and CA T assay. COS 1 and HeLa cells were plated on 60-mm dishes at a density adjusted so that they reached -60% confluence after overnight incubation. 4 (from nucleotide +600 to +627). 20 hybridization positives were isolated by the screening of -6 X I05 independent plaques and the inserts were subcloned into the EcoRI site of plasmid Ml 3mp 18 . Restriction endonuclease mapping of the cDNA clones suggested heterogeneity at the 5' termini of the cDNAs. Two classes of inserts consisting of 1,167 bp (cDNA-1) and 1,251 bp (cDNA-2) were identified. The entire cDNA-1 and cDNA-2 clones were sequenced in both directions. Comparison oftheir nucleotide sequences is shown in Fig. 1 . cDNA-1 corresponds to the published cDNA sequence of human preproET-1 ( 15). This clone, which terminates in a naturally occurring EcoRI site, lacks most of the 3'-UTR and the poly(A) tail. The whole 3'-UTR region of human preproET-1 was further cloned showing that it extends 849 nucleotides from the natural EcoRI site ( 17) . Differences between the two cDNAs are present only in the 5'-UTR. In fact cDNA-2 contains an 80-nucleotide extension at its 5' end. In human endothelial cells, the 5' end of preproET-1 mRNA was reported to be 268 nucleotides upstream of the translational start site ( 17) . Interestingly, the 5' leader sequence of the largest preproET-1 cDNA extended upstream of this putative transcription start site and included a TATA box element that has previously been shown to be essential for human ET-1 gene expression in endothelial cells (25).
Mapping 5' termini ofpreproET-J mRNAs. To characterize the precise transcriptional start sites of the two preproET-1 mRNAs, primer extension analysis was performed. For this purpose a primer covering nucleotides (nt) + 100 to nt +67 (oligo 1, Fig. 2 ), was used for extension experiments as well as to obtain the sequence ladder. In the presence of human placenta RNA a series of specific bands were obtained (Fig. 3 A) . Three of them confirmed the position of the preproET-1 mRNA transcriptional start site previously mapped with SI analysis ( 17) . Nevertheless little discrepancies were observed. Inoue and co-workers suggested that the cap site was at nt + 1 while our primer extension analysis indicated nt +2, +3, and +4 as potential transcriptional start site. Therefore Rsp Tyr Leu Leu Met lie Phe Ser Leu Leu Phe Ual Rio Cys Gin Gly Rio Pro Glu Thr Rio Ual Leu Gly Rio Glu Leu Ser GRT TRT TTG CTC RTG RTT TTC TCT CTG CTG TTT GTG GCT TGC CAR GGR GCT CCR GRR RCR GCR GTC TTR GGC GCT GRG CTC RGC +358 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Rio Ual Gly Glu Rsn Gly Gly Glu Lys Pro Thr Pro Ser Pro Pro Trp Rrg Leu Rrg Rrg Ser Lys Rrg Cys Ser Cys Ser Ser GCG GTG GGT GRG RRC GGC GGG GRG RRR CCC RCT CCC RGT CCR CCC TGG CGG CTC CGC CGG TCC RRG CGC TGC TCC TGC TCG TCC +442 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Leu fet Rsp Lys Glu Cys Ual Tyr Phe Cys His Leu Rsp lie lie Trp Ual Rsn Thr Pro Glu His Ual Val Pro Tyr Gly Leu CTG RTG GAT RAR GAG TGT GTC TAC TTC TGC CRC CTG GRC RTC RTT TGG GTC ARC ACT CCC GAG CRC GTT GTT CCG TAT GGR CTT +526 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Gly Ser Pro Rrg Ser Lys Rrg Rio Leu Glu Rsn Leu Leu Pro Thr Lys Rio Thr Asp Rrg Glu Rsn Rrg Cys Gin Cys Rla Ser GGR RGC CCT RGG TCC RAG AGA GCC TTG GAG RAT TTR CTT CCC RCA RAG GCR RCR GAC CGT GAG RAT RGR TGC CAR TGT GCT RGC +610 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ***
Gin Lys Rsp Lys Lys Cys Trp Rsn Phe Cys Gin Rla Gly Lys Glu Leu Rrg Rio Glu Rsp lie let Glu Lys Rsp Trp Rsn Rsn CAR ARR GAC RAG RAG TGC TGG RAT TTT TGC CAR GCR GGR RAR GRAR CTC RGG GCT GRA GAC RTT RTG GAG RAR GRC TGG RAT RAT +694
*** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** His Lys Lys Gly Lys Asp Cys Ser Lys Leu Gly Lys Lys Cys lie Tyr Gin Gin Leu Ual Rrg Gly Rrg Lys lie Rrg Rrg Ser CRT RAG RAR GGR RAR GAC TGT TCC RAG CTT GGG RAR RAG TGT RTT TAT CRG CRG TTR GTG AGA GGR AGA RAR RTC AGA AGA RGT +778 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Ser Glu Glu His Leu Rrg Gin Thr Rrg Ser Glu Thr fet Rrg Rsn Ser Ual Lys Ser Ser Phe His Rsp Pro Lys Leu Lys Gly TCR GAG GRA CRC CTR AGA CAR RCC RGG TCG GAG RCC RTG AGA ARC RGC GTC RAR TCR TCT TTT CRT GAT CCC RAG CTG RAR GGC +862 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Lys Pro Ser Rrg Glu Rrg Tyr Ual Thr His Rsn Rrg Rio His Trp RAG CCC TCC AGA GAG CGT TAT GTG RCC CRC RRC CGR GCR CRT TGG TGRCRGRCTTCGGGGCCTGTCTGRRGCCRTRGCCTCCRCGGRGRGCCCTGT +958 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *************************************************** GGCCGACTCTGCRCTCTCCRCCCTGGCTGGGRTCRGRGCRGGRGCRTCCTCTGCTGGTTCCTGRCTGGCRRRGGRCCRGCGTCCTCGTTCRRRRCATTCCRRGARRGGTTR +1069 RGGRGTTCCCCCRRCCRTCTTCRCTGGCTTCCRTCRGTGGTRRCTGCrTTGGTCTCTTCTTTCRTCTGGGGRTGRCRRTGGRCCTCTCRGCRGRRRCRCRCRGTCRCATTC +1180 GRRTTC +1186 Figure 1 . Sequences of cDNA-1 and cDNA-2 clones. The upper line represents the sequence of cDNA-2; the lower line represents the cDNA-I sequence. *Indicates the same nucleotide. The TATA box element of the known preproET-1 promoter is included in the cDNA-2 sequence (underlined). Cap (nucleotide + 1 ), represents the position of the previously mapped transcription start site of the human preproET-1 gene ( 17) . A naturally occurring EcoRI site is located at the 3' end of both cDNAs.
were detected. To locate more precisely the positions of these transcribed either with oligo 1 and oligo 2, demonstrating the other potential cap sites a primer covering nt -99 to nt -129 specificity of the extension products obtained with placenta (oligo 2, Fig. 2 ), and positioned upstream to the 5' end of RNA (not shown). To verify whether these multiple cap sites cDNA-2 was used. Elongation of this primer on total human are located to an alternative 5' exon or are directly upstream to placenta RNA yielded a series of bands (Fig. 3 B) suggesting the 5' end of cDNA-2, PCRs were performed with total plathe existence of multiple transcriptional start sites upstream to centa RNA. One of the primers, covering nt +44 to nt +24, the functional CAAT and TATA boxes of the preproET-1 pro-(oligo 3, Fig. 2 ) was invariant and was used as antisense oligo; moter region (25 (Methods) . The chimeric genes were transfected into COS-1 (renal epithelial) cells and assayed for promoter activity comparing CAT expression driven by a series of 5' promoter deletion mutants to the CAT expression driven by the full length parental CAT construct -1 505CAT. As shown in Fig. 5 , the construct (-1505CAT) was able to induce a high level of CAT gene expression above the background. The level ofCAT was drastically reduced when the deletion was extended to nt -647 (-647CAT). Interestingly, a deletion to nt -127 (-127CAT), restored promoter activity, while plasmid -99CAT was associated with only threefold lower CAT activity. Further deletions of the CAAT box (-70CAT) and the TATA box (-25CAT), reduced CAT expression to the background level. These data indicate the presence ofa negative regulatory region (-647 To analyze the tissue distribution of the two preproET-1 mRNAs primer extension was performed. Oligo 1 (see Fig. 2) was used for extension experiments as well as to obtain the sequence ladder. As shown in Fig. 7 there is a selectivity in the expression of mRNA-1 and mRNA-2. In fact, while in the presence of placenta or kidney RNA (lanes I and 2) a series of bands specific for the two mRNAs were detected, extension analysis with heart and brain RNA (lanes 3 and 4, respectively), revealed the existence ofonly mRNA-2 in these tissues.
preproET-J cell-type-specific expression. Several types of cultured cells were analyzed by Northern blot hybridization and by RIA to detect ET-1 expression (not shown). Among these, COS-1 (renal epithelial) cells expressed ET-1, while HeLa (epidermoid carcinoma) did not. These cell lines were therefore chosen for transfection to evaluate DNA regions potentially involved in the cell-type specific regulation of preproET-1 gene. In contrast to the high level of CAT expression driven by fusion plasmids -1 505CAT, -1 27CAT, and -99CAT in COS-1 cells, all of them showed weak activity in HeLa cells (not shown). These data indicate that -127CAT contains sequence necessary for preproET- 1 -129 to -40 (including potentially important flanking sequences) was inserted upstream to an heterologous promoter fused to the CAT gene. This construct was used to transfect COS-1 and HeLa cells (Fig. 8) . This could partially explain the presence of putative multiple transcription initiation sites showed by primer extension. In fact, many genes lacking 5' TATA sequences often display heterogeneity of transcript initiation. Interestingly, the upstream promoter region ofthe preproET-1 gene contains three CAATlike sequences as observed in the case of the upstream promoter of the pyruvate kinase gene (36) . To verify whether these sequences have any functional role, deletion and point mutation analysis of this region is under investigation.
Sequence requirement for preproET-1 expression in endothelial cells has been recently investigated (25) (26) (27) . Two DNA regions were found to be important for constitutive expression ofthe preproET-1 gene in endothelial cells: region A, located at bp -148 to -117, and region B, located at bp -117 to -98 (25). The emerging role of ET-1 in renal pathophysiology (37) prompt us to investigate the role of cis-acting sequences in preproET-1 expression in the kidney. Recently, we showed that ET-I is constitutively expressed by mesangial cells and that it is regulated by factors potentially released by inflammatory cells and platelets infiltrating the glomerular tuft during the course of various types of glomerulonephritis (5) . Monkey kidney epithelial (COS-1) cells were used for our studies because attempts to transfect mesangial cells were unsuccessful. Using deletion mutants and enhancer trap experiments we have identified an 89-bp region, located at bp -129 to -40 of the preproET-1 gene, necessary for its expression in kidney epithelial cells. These data contrast with those obtained by other authors. Wilson and co-workers, identified a nonerythroid GATAbinding protein which binds to a GATA motif located at bp -135 to -132, region A, and which is required for preproET-1 promoter function (26) . Surprisingly, a deletion mutant (-127CAT), which excludes this GATA element, is sufficient to drive high level ofCAT expression in COS-1 cells. Molecular cloning of the GATA protein (GATA-2) responsible for preproET-1 gene expression in endothelial cells has been recently described (27) . Transactivation experiments showed that while GATA-2 was effective at activating reporter constructs carrying region A in endothelial cells, on the contrary it was completely ineffective in COS cells (27) . Altogether these data suggest that different mechanisms control preproET-1 gene expression in renal epithelial cells as compared to endothelial cells.
ET-1 has surprisingly potent and wide ranging biological activities. In the last three years, many attempts have been focused to understand the mechanisms controlling the processing of its inactive precursor. Recently, we reported that human preproET-1 follows the constitutive secretory pathway and undergoes posttranslational polypeptide maturation when expressed in Xenopus oocytes (21 ) . We therefore suggested that regulation of ET-1 secretion occurs mainly at transcriptional level. The data presented herein strengthen this hypothesis. An open question that deserve further investigation is the biological relevance of the tissue-specific expression of mRNA-1 and mRNA-2. Previous observations have indicated that plasma levels of ET-1 in humans are elevated after acute myocardial infarction (38) . Interestingly, the "acute phase reactant regulatory elements" CTGGGA, thought to mediate the induction of the mRNA under acute physical stress in vivo (39, 40) , is present in the region mapped as preproET-1 upstream promoter. Moreover, the presence of only mRNA-2 in heart tissue may suggest the existence of specific mechanisms controlling ET-1 gene expression under pathophysiological events such as myocardial infarction.
